Key modelling data for UCB full-year results 2022 and reminders for 2023

As of 23 January 2023

UCB IR Team has compiled the following items to assist capital market participants in preparation of the upcoming FY results 2022 publication, scheduled for February 22, 2023.

This document contains forward-looking statements, including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. There can be no guarantee that the investigational or approved products potentially described in this presentation will be or will continue to be commercially successful in the future. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this presentation, and do not reflect any potential impacts from the evolving COVID-19 pandemic, unless indicated otherwise. UCB continues to follow the development diligently to assess the financial significance of this pandemic to UCB. Information contained in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

UCB expressly disclaims any obligation to update any forward-looking statements in this presentation, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

In the event of any differences between this presentation and the Integrated Annual Report or Half Year Report, the information included in the Report shall prevail.

HY22 financial results
Slide 24 in the HY22 presentation
Link to HY22 report

Guidance 2022 updated on June 24, 2022
Revenue: €5.30 - 5.40bn
Adjusted EBITDA: 21 - 22%
Core EPS: €3.70 - 4.00
Tax guidance: "Around 17%"
R&D ratio: ~30%

Main drivers for updated guidance 2022
Zogenix acquisition (2.5% margin dilutive in 2022, accretive from 2023 onwards)
Inflation pressure (e.g. Belgian wage indexation, these wages constitute approx. 1/6 of total OPEX)
Bimzelx® CRL in the US
Vimpat LoF in US and EU
Financial update on January 9, 2023

- 2022 total revenue and adjusted EBITDA margin at the upper end of the guided range: Reaching the upper end of UCB’s financial guidance – despite the macroeconomic headwinds – is mainly driven by the solid performance of the company’s core products, like Cimzia® (certolizumab pegol) and Vimpat® (lacosamide), as well as cost discipline, wise resource allocations, efficiencies and the meanwhile successful finished integration of Zogenix (acquired in March 2022) being less dilutive than expected.

- Cimzia® reached its peak sales target of €2bn in 2022
- Fintepla® peak sales expected to reach €800 million by 2027

Guidance 2023
Will be announced at FY22 results, on 22 February 2023

Guidance 2025 confirmed
Revenue: at least €6bn
Adjusted EBITDA: low- to mid-thirties %
Improved ESG rating performance

Vimpat®
US: Loss of exclusivity March 2022
   Expected sales erosion approx. -80% over the first 12 months
EU: Loss of exclusivity September 2022
   Expected sales erosion approx. -50% over the first 24 months
Expectations based on Keppra erosion after its LoE, excluding special effects

Cimzia®
Peak sales guidance: >€2.0bn by 2024 – achieved in 2022
US: Loss of exclusivity February 2024¹
EU: Loss of exclusivity October 2024¹
Current assumption for first possible biosimilar market entry: Early 2026

E Keppra®
Generic erosion in Japan started January 2022, stronger than expected

Evenity®
Evenity is developed and commercialized in collaboration with Amgen globally, as well as with Astellas in Japan
UCB books the European sales and European opex, Amgen books US, Japan and RoW sales
Net Profit split booked in “Other operating income”
Amgen reported Q3/2022 net sales of $US 201mn and YTD net sales of $US 562mn (Slide 13 in Amgen’s Q3 presentation)

bimekizumab/Bimzelx®
EU: Launched for Psoriasis (PSO) in Germany, UK, The Netherlands, Sweden, France, Italy, Spain, Czech Republic, Belgium; Goal to reach 80% of EU population by end 2022
Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA) applications filed in September
US: Resubmission for PSO in November 2022 after CRL from May 2022 due to pre-approval inspection observations related to filling of the product; validated and classified by FDA in December 2022 (Class 2 review with a 6 months review time), expected FDA action: Q2 2023
Japan: Launched for PSO
RoW: Launched for PSO in Canada, Australia, Saudi Arabia, Switzerland
Dynamic share (new and switch patients) in the IL17 market trends to 25% one year after launch across geographies
Three-year data presented for PSO in September and 52-week data presented for PsA and axSpA in November
Hidradenitis suppurativa (HS) phase 3 positive topline results announced on 9 December 2022
Fintepla®
Achieved €35mn sales for the period March-June 2022 (since completion of the Zogenix acquisition)
Approved in the US for treatment of Lennox-Gastaut syndrome (LGS) in March 2022 and in Japan for treatment of Dravet syndrome in September 2022
Positive CHMP opinion for LGS in December 2022

rozanolixizumab
Filed in US (priority review) and EU, feedback expected from Q2/2023
Latest data (MuSK+ patients, responder analysis, safety analysis) presented at AANEM in September 2022

zilucoplan
Filed in EU and US, feedback expected in Q4/2023
Latest data (24-week analysis, quality-of-life (QoL) outcomes, responder analysis) presented at AANEM in September 2022

M&A and BD activities
Zogenix: Acquisition in March 2022 for a total transaction value of €1.7bn (US$ 26.00 per share & CVR of US$ 2.00)
Consideration includes a contingent value right (CVR) for a potential cash payment of US$ 2.00 upon EU approval by December 31, 2023, of FINTEPLA® as an orphan medicine for treatment of Lennox-Gastaut syndrome (LGS)

ESG
MSCI rating improved to AA from A, which puts UCB in the top quartile of the pharma industry
Targets summary and ESG presentation slides on our website

Pipeline
Pipeline on our website
Update due Feb 22, 2023

1 Loss of exclusivity dates are indicative.